Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006 Nov;92(11):1603-9.
doi: 10.1136/hrt.2005.082560. Epub 2006 May 18.

Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure

Affiliations
Randomized Controlled Trial

Short-term statin treatment improves endothelial function and neurohormonal imbalance in normocholesterolaemic patients with non-ischaemic heart failure

C H Strey et al. Heart. 2006 Nov.

Abstract

Objectives: To investigate the effect of short-term statin treatment on impaired endothelium-dependent vasodilatation and haemodynamic abnormalities typically occurring in chronic heart failure (CHF).

Methods: In a double-blind, crossover study endothelium-dependent vasodilatation was measured in conduit and resistance vessels of 23 patients with non-ischaemic CHF after 6 weeks of placebo and 40 mg atorvastatin. The haemodynamic impact was assessed by cardioendocrine hormones, echocardiography and clinical indicators of CHF.

Results: Cholesterol concentrations were population average (low density lipoprotein 3.56 (SEM 0.16) mmol/l, triglycerides 1.70 (0.20) mmol/l and high density lipoprotein 1.17 (0.07) mmol/l). In resistance vessels, the area under the curve ratio during acetylcholine infusion increased from 9.2 (1.9) with placebo to 12.2 (2.1) with statin (p < 0.01). This improvement was reversed during co-infusion with the nitric oxide antagonist N(G)-monomethyl-L-arginine. In conduit arteries, flow-mediated dilatation increased from 5.64 (SEM 0.88)% with placebo to 6.83 (0.97)% with statin (p < 0.05). Endothelium-independent vasodilatation did not change (p = 0.68 for conduit and p = 0.45 for resistance vessels). Endothelin 1 and atrial natriuretic peptide (ANP) decreased from 1.57 (0.08) and 51.3 (1.0) with placebo to 1.42 (0.09) pg/ml (p < 0.05) and 42.1 (7.5) pmol/l (p < 0.05), respectively, with statin.

Conclusions: In patients with non-ischaemic CHF and population-average cholesterol concentrations, short-term statin treatment improves endothelial function in conduit and resistance vessels and lowers plasma endothelin 1 and ANP concentrations.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment in

  • Heart failure: statins for all?
    Leite-Moreira AF, Castro-Chaves P. Leite-Moreira AF, et al. Heart. 2006 Nov;92(11):1537-8. doi: 10.1136/hrt.2006.089797. Epub 2006 Apr 10. Heart. 2006. PMID: 16606859 Free PMC article.

References

    1. Kubo S H, Rector T S, Bank A J.et al Endothelium‐dependent vasodilation is attenuated in patients with heart failure. Circulation 1991841589–1596. - PubMed
    1. Drexler H. Endothelium as a therapeutic target in heart failure. Circulation 1998982652–2655. - PubMed
    1. Rauchhaus M, Coats A J, Anker S D. The endotoxin‐lipoprotein hypothesis. Lancet 2000356930–933. - PubMed
    1. Krum H, McMurray J J. Statins and chronic heart failure: do we need a large‐scale outcome trial? J Am Coll Cardiol 2002391567–1573. - PubMed
    1. O'Driscoll G, Green D, Taylor R R. Simvastatin, an HMG‐coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997951126–1131. - PubMed

Publication types